Wednesday, June 10, 2015

FDA Advisers Say Amgen's Cholesterol Drug Should Be Approved

(MedPage Today) -- Panel votes 11-4 that the PCSK9 inhibitor evolocumab may be appropriate for some groups
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)